GGrantIndex
← Leaderboards

Microbiotix, Inc

Worcester, MA

Compare ↔
$122,975,711
Total funding
92
Grants

Funding over time

peak $8.2M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$122,975,711 · 92

By mechanism

R44$41,822,504 · 13
R43$28,012,976 · 52
U01$14,933,794 · 2
R01$12,967,240 · 3
N01$12,271,595 · 2
R41$9,503,048 · 16

Investigators at Microbiotix, Inc

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Gai Liu$3,152,9336 gr2Islam Hussein$585,1911 gr

All-Time

Most funded here, all years

1Terry L Bowlin$18,753,37615 gr2Michelle M. Butler$16,920,91713 gr3Arnab Basu$8,577,0065 gr4Norton P Peet$3,225,5214 gr5Gai Liu$3,152,9336 gr6John D Williams$1,382,6433 gr7Marjorie H Barnes$822,9022 gr8Bing Li$599,9991 gr

Largest grants

DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS$2,938,788
N01 · FY2025 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,742,219
N01 · FY2025 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,485,753
N01 · FY2024 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$2,219,077
U01 · FY2009 · AI
DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS$2,069,416
N01 · FY2023 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,930,692
U01 · FY2006 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,909,652
U01 · FY2010 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,611,536
U01 · FY2008 · AI
Novel Small Molecule Inhibitors of Botulinum Neurotoxin A$1,594,896
U01 · FY2007 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,432,109
R01 · FY2017 · AI
A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION$1,428,397
R44 · FY2006 · AI
A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION$1,367,168
R44 · FY2005 · AI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,334,916
U01 · FY2011 · AI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,174,338
U01 · FY2012 · AI
Discovery of B. pseudomallei therapeutics for Biodefense$1,170,128
R44 · FY2007 · AI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,149,999
U01 · FY2009 · AI
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens$1,124,408
U01 · FY2010 · AI
A Potent Oral Therapy for Cytomegalovirus Infection$1,124,230
R44 · FY2008 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,114,898
R01 · FY2018 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,100,543
R01 · FY2019 · AI